Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ALK+ Advanced NSCLC × brigatinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Lung Neoplasms 4 Neuroma, Acoustic 1 Neurofibromatosis 2 1 NSCLC 1 Meningioma 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Ependymoma 1 ALK-positive Advanced NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡